Sept 14 (Reuters) - Kalvista Pharmaceuticals Inc
* KalVista pharmaceuticals reports fiscal first quarter results
* Q1 loss per share $0.51
* Q1 revenue $100,000 versus $1.0 million
* KalVista Pharmaceuticals Inc - Intravitreal Diabetic Macular Edema Candidate KVD001 remains on track for Phase 2 in 2017
* KalVista Pharmaceuticals Inc - cash and cash equivalents were $26.5 million as of July 31, 2017 Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.